E
Erydel
Red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases
About Erydel
EryDel is a biotechnology company focused on developing and commercializing specialized therapies for the treatment of rare diseases. The company utilizes a proprietary platform technology that encapsulates therapeutic enzymes and other molecules within red blood cells. This innovative approach allows for prolonged half-life in circulation, reduced immunogenicity, better tolerability, and predictable vascular distribution. EryDel primarily serves patients suffering from rare diseases, offering them advanced therapeutic options that are not widely available in the market. The company operates in the biopharmaceutical sector, targeting niche markets with high unmet medical needs. EryDel's business model revolves around research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through the sale of these specialized treatments, as well as potential partnerships and licensing agreements with other pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2007
- Headquarters
- Bresso, Italy
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 67.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Neurology, Spinout, Disease, Biotech and Pharma, Cell Therapy, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Oct 2023 | $485M | $485M | Quince Therapeutics | ↗ |
| SERIES COther financing | Feb 2020 | $23M | $92M | Sofinnova Partners | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Erydel is 280 monthly website visits, up 55.6% over the last three months. Erydel's team declined 34.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Innogest Capital
Genextra
Finlombarda Gestioni SGR
Sofinnova Partners
Other known investors2 additional known investors
Quince Therapeutics
University of Urbino
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Erydel on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Erydel’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.